Atea Pharmaceuticals Stock Piotroski F Score

AVIR Stock  USD 3.37  0.12  3.69%   
This module uses fundamental data of Atea Pharmaceuticals to approximate its Piotroski F score. Atea Pharmaceuticals F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Atea Pharmaceuticals. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Atea Pharmaceuticals financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Atea Pharmaceuticals Altman Z Score, Atea Pharmaceuticals Correlation, Atea Pharmaceuticals Valuation, as well as analyze Atea Pharmaceuticals Alpha and Beta and Atea Pharmaceuticals Hype Analysis.
To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.
  
As of 11/23/2024, Net Debt is likely to drop to about (148.5 M). In addition to that, Short Term Debt is likely to drop to about 527.8 K. At this time, Atea Pharmaceuticals' Price Book Value Ratio is relatively stable compared to the past year. As of 11/23/2024, Ebt Per Ebit is likely to grow to 1.03, though Free Cash Flow Yield is likely to grow to (0.32).
At this time, it appears that Atea Pharmaceuticals' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Increase

Focus
Change in Gross Margin

No Change

Focus

Atea Pharmaceuticals Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Atea Pharmaceuticals is to make sure Atea is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Atea Pharmaceuticals' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Atea Pharmaceuticals' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.210.41
Way Down
Slightly volatile
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
Total Current Liabilities57 M32.4 M
Way Up
Slightly volatile
Non Current Liabilities TotalM7.4 M
Notably Down
Slightly volatile
Total Assets541.8 M595 M
Significantly Down
Slightly volatile
Total Current Assets539.7 M590.5 M
Significantly Down
Slightly volatile

Atea Pharmaceuticals F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Atea Pharmaceuticals' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Atea Pharmaceuticals in a much-optimized way.

About Atea Pharmaceuticals Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

3.76

At this time, Atea Pharmaceuticals' Book Value Per Share is relatively stable compared to the past year.

Atea Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Atea Pharmaceuticals from analyzing Atea Pharmaceuticals' financial statements. These drivers represent accounts that assess Atea Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Atea Pharmaceuticals' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap2.5B3.4B740.4M400.4M254.3M241.6M
Enterprise Value2.5B2.6B(23.8M)(243.2M)112.9M107.3M

Atea Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Atea Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Atea Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

About Atea Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Atea Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atea Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atea Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Atea Stock

  0.71VALN Valneva SE ADRPairCorr
  0.63VCNX VaccinexPairCorr

Moving against Atea Stock

  0.72BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.62EWTX Edgewise TherapeuticsPairCorr
  0.61GILD Gilead SciencesPairCorr
  0.48KZR Kezar Life SciencesPairCorr
  0.45VRDN Viridian TherapeuticsPairCorr
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.